DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DarioHealth Corp. on October 22, 2021. The report details the entry into a material definitive agreement regarding the potential sale of common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to raise up to $50 million in aggregate offering price through the sale of common stock.
Material Changes and Agreements
- Sales Agreement: On October 22, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC as agent.
- Offering Structure: The Company may issue and sell shares of common stock with an aggregate offering price of up to $50 million from time to time.
- Sale Methods: Sales may be conducted via privately negotiated transactions or "at the market" offerings (Rule 415(a)(4)), including block transactions or sales on The Nasdaq Capital Market.
- Compensation: The Company will pay Cowen a cash commission of up to 3.0% of the gross proceeds from any shares sold.
- Registration Status: The offering relies on a shelf registration statement on Form S-3, which has been filed but is not yet effective. No sales can occur until the statement is declared effective by the SEC.
Guidance, Outlook, and Risks
The Company is not obligated to make any sales under the agreement. There is no assurance that any shares will be sold, nor is there any guarantee regarding the price, number of shares, or timing of potential sales. The agreement may be terminated by either party as set forth in its terms.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 Registration Statement referenced in the filing.
- Monitor future filings for actual sales activity, share counts, and pricing under the Sales Agreement.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Confirm the Company's current cash position and capital needs to assess the likelihood of utilizing the full $50 million capacity.